Does Earnings Surprise History Hold Any Clue for NYSE:HIMS, NYSE:EMX, NASDAQ:PIRS, NASDAQ:SYTA

HIMS & HERS HEALTH (NYSE:HIMS) EARNINGS INFORMATION (NYSE:HIMS)

Hims & Hers Health last announced its quarterly earnings results on May 17th, 2021. The reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. The firm earned $52.31 million during the quarter, compared to the consensus estimate of $48.74 million. Hims & Hers Health has generated $0.00 earnings per share over the last year. Hims & Hers Health has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 16th, 2021 based off prior year’s report dates.

IS HIMS & HERS HEALTH A BUY RIGHT NOW? (NYSE:HIMS)

8 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Hims & Hers Health in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Hims & Hers Health stock.
Hims & Hers Health

EMX ROYALTY EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NYSE:EMX)

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN EMX ROYALTY? (NYSE:EMX)

Wall Street analysts have given EMX Royalty a “N/A” rating, but there may be better buying opportunities in the stock market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but EMX Royalty wasn’t one of them. MarketBeat thinks these five companies may be even better buys.

PIERIS PHARMACEUTICALS (NASDAQ:PIRS) EARNINGS INFORMATION (NASDAQ:PIRS)

Pieris Pharmaceuticals last announced its quarterly earnings data on May 17th, 2021. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.10. Pieris Pharmaceuticals has generated ($0.56) earnings per share over the last year. Pieris Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 9th, 2021 based off prior year’s report dates.

IS PIERIS PHARMACEUTICALS A BUY RIGHT NOW? (NASDAQ:PIRS)

2 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Pieris Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Pieris Pharmaceuticals stock.
Pieris Pharmaceuticals

SIYATA MOBILE EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NASDAQ:SYTA)

IS SIYATA MOBILE A BUY RIGHT NOW? (NASDAQ:SYTA)

1 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Siyata Mobile in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should “buy” Siyata Mobile stock.
Siyata Mobile